An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study (genetically engineered mice)
PubMed 25610726 · doi:10.4161/21624011.2014.944047
What was done
Researchers evaluated the antitumor response to the anthracycline mitoxantrone (MTX) in a genetically engineered mouse melanoma model driven by 4-hydroxy-tamoxifen-induced activation of oncogenic Braf and deletion of Pten. Mice with intact autophagy (Atg7+/+) were compared to those with conditional deletion of the essential autophagy gene Atg7 (Atg7fl/fl). The dependency of the response on adaptive immunity was assessed by depleting CD4+ or CD8+ T lymphocytes.
What was found
The abstract reports directional findings without numerical values or statistical metrics. Systemic mitoxantrone treatment reduced tumor growth in autophagy-competent melanomas (Braf^Ca/+ Pten^fl/fl Atg7^+/+) but failed to affect tumor progression in autophagy-deficient melanomas (Braf^Ca/+ Pten^fl/fl Atg7^fl/fl). Furthermore, the growth-inhibitory effect of mitoxantrone on autophagy-competent tumors was completely abolished following the combined depletion of CD4+ or CD8+ T lymphocytes.
Why it matters
This study extends findings previously seen in transplantable tumor grafts to an autochthonous, genetically engineered model, confirming that chemotherapy-induced tumor suppression relies on tumor-cell autophagy to trigger a protective T-cell immune response.
Limits
Findings are restricted to preclinical mouse models and may not fully reflect human clinical responses. The abstract does not provide sample sizes, quantitative effect sizes, survival metrics, or statistical significance levels. Testing was limited to one chemotherapeutic agent (mitoxantrone) in a specific Braf/Pten-driven genetic background.
Cited by
- partial Long-term clinical efficacy of chemotherapy depends on inducing cancer cell death that elicits an anti-cancer immune response via autophagy induction.